The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease

NCT02546609 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

91

Enrollment

INDUSTRY

Sponsor class

Conditions

NAFLD

Interventions

DRUG: Leu-Met-Sil 0.5
DRUG: Leu-Met-Sil 1.0
DRUG: Placebo

Sponsor

NuSirt Biopharma